At Rigel Pharmaceuticals, we are dedicated to improving the lives of patients through the discovery, development, and commercialization of novel small molecule drugs.
In particular, we are focused on hematologic disorders, cancer and rare immune diseases. We see great opportunity to help patients who have diseases where few or no approved treatment options exist.
The company’s first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets*, the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. ITP is a rare autoimmune disease where the body’s own immune system attacks and destroys platelets in the blood.
TAVALISSE is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.
Fostamatinib is currently being studied in a Phase 3 clinical trial for the treatment of warm antibody autoimmune hemolytic anemia (AIHA); a Phase 3 clinical trial for the treatment of hospitalized COVID-19 patients; an NIH/NHLBI-sponsored Phase 2 clinical trial for the treatment of hospitalized COVID-19 patients, in collaboration with Inova Health System; and a Phase 2 clinical trial for the treatment of COVID-19 patients being conducted by Imperial College London.
Our other clinical programs include an ongoing Phase 1 study of R835, an investigational molecule from our interleukin receptor-associated kinase (IRAK) inhibitor program, and a completed Phase 1 study of R552, an investigational molecule from our receptor-interacting serine/threonine-protein kinase (RIPK) inhibitor program. Rigel recently entered into a collaboration with Lilly to develop Rigel’s RIPK1 inhibitors in immunological and neurodegenerative diseases.
In addition, Rigel continues to build an extensive portfolio of investigational agents, which are being developed with our other partners. These products are focused on the inhibition of select signaling pathways, including Axl tyrosine kinase (AXL), Janus kinase (JAK), and murine double minute 2 (MDM2). Through strategic partnerships and collaborations, we are able to take advantage of additional experience and resources, while benefiting from the potential success of these future products, both through milestone payments and royalties.
At Rigel, we are able to leverage our wealth of in-house talent and we anticipate continued growth in our pipeline from ongoing pre-clinical efforts of our highly experienced research and development teams.
* Please see the TAVALISSE full prescribing information